Short answer
Jade Biosciences, Inc. (JBIO) filed an 8-K current report with the SEC on June 26, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Mark Eisner, M.D., M.P.H. appointed Class I director through 2028 annual meeting.
Jade Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Mark Eisner, M.D., M.P.H. appointed Class I director through 2028 annual meeting
- Former Vir Biotechnology chief medical officer adds clinical, regulatory, and medical-affairs expertise
- Nominating and Corporate Governance Committee appointment strengthens board governance capabilities
- 47,675-share stock option granted, vesting monthly over three years
- Option accelerates fully upon change in control, subject to continued service
Item 7.01 · Regulation FD Disclosure
- Dr. Eisner elected to Jade Biosciences’ Board, adding a new director-level leadership resource
- Press release furnished as Exhibit 99.1, with the appointment announcement dated June 26, 2026
Item EX-99.1 · Exhibit EX-99.1
- Mark Eisner appointed to Jade’s board effective June 25, 2026
- More than 25 years in clinical development and immunology, including Genentech/Roche and Vir Biotechnology leadership
- Appointment strengthens strategic and regulatory expertise as Jade advances autoimmune antibody programs
- JADE101 targets APRIL for immunoglobulin A nephropathy; JADE201 and JADE301 expand pipeline potential
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Jade Biosciences, Inc. 8-K filings
Get the next JBIO 8-K as it lands
Follow JBIO for push alerts, or ask the research agent what this filing means.